RxDoctor Payments Data

Scott Gawlik, DPM

Podiatrist · Brooklyn, NYNPI 1043246085

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Kerecis Limited accounts for 77.3% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $25,327, more than ten times the $1,651 reported in 2019. Among podiatrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$76,720in general payments, 2019–2025

Across 289 payments — averaging $265.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$59K
  • Stryker$9K
  • Smith+Nephew$3K
  • Abbott$573
  • Treace Medical Concepts, Inc.$547
  • Tactile Systems Technology Inc$527
  • plus $4K from 29 others

What the payments were for

  • Consulting fees$6,3508%
  • Speaking & faculty fees$41,25054%
  • Travel & lodging$7,52510%
  • Food & beverage$19,79526%
  • Education$1,8002%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,720 in reported general payments places this provider in the 95th percentile of 862 podiatrist providers in New York.

See all podiatrist providers in New York

Medicare billing

Part B allowed, 2024
$101,877
Medicare patients
346
Services billed
1,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.30$14,667
Mupirocin71$506
Diclofenac Sodium37$397
CiclopiroxCiclopirox Olamine20$382
Ammonium Lactate13$350
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav42$319
Ciclopirox11$253
Terbinafine Hcl32$239
Cefadroxil17$114
Doxycycline Hyclate13$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$2,559$14,66730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 862 podiatrist providers in New York.

Other podiatrist in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →